Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Exjade Extended Phase IV Studies Recommended

Executive Summary

Long-term Phase IV studies of Novartis' oral iron chelator Exjade in various transfusion populations were recommended by the Blood Products Advisory Committee at its meeting on Sept. 29

You may also be interested in...



Exjade Pediatric Registry Testing Frequency May Be Reduced, Subcmte. Says

Safety monitoring in Novartis' Exjade post-approval pediatric patient registry could be reduced in frequency during the term of the five-year registry, FDA's Oncologic Drugs Advisory Committee, Pediatric Oncology Subcommittee suggested

Exjade Pediatric Registry Testing Frequency May Be Reduced, Subcmte. Says

Safety monitoring in Novartis' Exjade post-approval pediatric patient registry could be reduced in frequency during the term of the five-year registry, FDA's Oncologic Drugs Advisory Committee, Pediatric Oncology Subcommittee suggested

Advisory Committees In 2006: FDA Advisory Cmte. Reviews To Focus More On Lifecycle Of Drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS046385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel